New clinical data demonstrate excellent lesion durability with pulseselect™ pulsed field ablation system in real-world setting as approvals and adoption expand globally

Aphrs: new data confirm robust long-term durability and highly efficient procedure performed without fluoroscopy successful launch in japan follows recent reimbursement approval   approvals across apac including china and australia broaden reach for patients galway, ireland and sydney, sept. 27, 2024 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced the presentation of clinical study results demonstrating a high rate of durable lesion formation for the pulseselect™ pulsed field ablation (pfa) system in treating atrial fibrillation (afib).
MDT Ratings Summary
MDT Quant Ranking